Stifel Financial Corp reduced its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 80.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 60,610 shares of the life sciences company’s stock after selling 254,113 shares during the quarter. Stifel Financial Corp’s holdings in Illumina were worth $12,072,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in Illumina by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 9,904,340 shares of the life sciences company’s stock valued at $1,718,601,000 after purchasing an additional 255,498 shares during the period. Ameriprise Financial Inc. increased its stake in shares of Illumina by 3.1% in the third quarter. Ameriprise Financial Inc. now owns 2,512,167 shares of the life sciences company’s stock worth $500,416,000 after acquiring an additional 76,452 shares during the last quarter. Capital World Investors increased its stake in shares of Illumina by 23.8% in the second quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock worth $370,465,000 after acquiring an additional 410,000 shares during the last quarter. TIAA CREF Investment Management LLC increased its stake in shares of Illumina by 55.6% in the second quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock worth $256,058,000 after acquiring an additional 527,548 shares during the last quarter. Finally, Winslow Capital Management LLC acquired a new position in shares of Illumina in the second quarter worth $211,584,000. 91.75% of the stock is currently owned by institutional investors.
Shares of Illumina, Inc. (NASDAQ:ILMN) opened at $217.65 on Monday. The stock has a market cap of $31,780.00, a price-to-earnings ratio of 63.64, a P/E/G ratio of 3.59 and a beta of 0.79. Illumina, Inc. has a fifty-two week low of $121.47 and a fifty-two week high of $230.72. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.12. The firm had revenue of $714.00 million during the quarter, compared to analysts’ expectations of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. Illumina’s revenue for the quarter was up 17.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.97 earnings per share. analysts anticipate that Illumina, Inc. will post 3.75 EPS for the current fiscal year.
In other Illumina news, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction dated Tuesday, December 5th. The shares were sold at an average price of $212.55, for a total transaction of $4,251,000.00. Following the completion of the sale, the director now directly owns 505,980 shares in the company, valued at $107,546,049. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Charles Dadswell sold 145 shares of the company’s stock in a transaction dated Tuesday, October 3rd. The shares were sold at an average price of $202.23, for a total transaction of $29,323.35. The disclosure for this sale can be found here. Insiders sold 166,150 shares of company stock valued at $34,767,331 over the last quarter. 0.89% of the stock is currently owned by corporate insiders.
A number of research firms have recently weighed in on ILMN. Wells Fargo & Company reaffirmed a “market perform” rating and issued a $205.00 price target (up from $200.00) on shares of Illumina in a research note on Wednesday, October 25th. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $252.00 price target on the stock in a research note on Tuesday, December 5th. BidaskClub downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research note on Wednesday, December 6th. Bank of America upped their price target on shares of Illumina from $215.00 to $240.00 and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Finally, Vetr raised shares of Illumina from a “hold” rating to a “buy” rating and set a $217.50 price target on the stock in a research note on Tuesday, September 19th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $201.98.
TRADEMARK VIOLATION NOTICE: “Illumina, Inc. (ILMN) Holdings Cut by Stifel Financial Corp” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.dispatchtribunal.com/2017/12/11/illumina-inc-ilmn-holdings-cut-by-stifel-financial-corp.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.